- Home
- BIOX vs DRUG Comparison
BIOX vs DRUG Comparison
Compare BIOX & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOX
- DRUG
- Stock Information
- Founded
- BIOX 2001
- DRUG 2019
- Country
- BIOX Argentina
- DRUG United States
- Employees
- BIOX N/A
- DRUG N/A
- Industry
- BIOX Agricultural Chemicals
- DRUG Pharmaceuticals and Biotechnology
- Sector
- BIOX Industrials
- DRUG Health Care
- Exchange
- BIOX Nasdaq
- DRUG Nasdaq
- Market Cap
- BIOX 168.3M
- DRUG 199.7M
- IPO Year
- BIOX N/A
- DRUG N/A
- Fundamental
- Price
- BIOX $2.77
- DRUG $38.57
- Analyst Decision
- BIOX Strong Buy
- DRUG Strong Buy
- Analyst Count
- BIOX 4
- DRUG 8
- Target Price
- BIOX $8.38
- DRUG $83.60
- AVG Volume (30 Days)
- BIOX 279.5K
- DRUG 51.4K
- Earning Date
- BIOX 09-08-2025
- DRUG 08-11-2025
- Dividend Yield
- BIOX N/A
- DRUG N/A
- EPS Growth
- BIOX N/A
- DRUG N/A
- EPS
- BIOX N/A
- DRUG N/A
- Revenue
- BIOX $383,289,394.00
- DRUG N/A
- Revenue This Year
- BIOX N/A
- DRUG N/A
- Revenue Next Year
- BIOX $7.30
- DRUG N/A
- P/E Ratio
- BIOX N/A
- DRUG N/A
- Revenue Growth
- BIOX N/A
- DRUG N/A
- 52 Week Low
- BIOX $2.60
- DRUG $0.94
- 52 Week High
- BIOX $11.39
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- BIOX 35.91
- DRUG 59.58
- Support Level
- BIOX $2.63
- DRUG $42.04
- Resistance Level
- BIOX $2.89
- DRUG $45.00
- Average True Range (ATR)
- BIOX 0.19
- DRUG 2.89
- MACD
- BIOX 0.02
- DRUG -0.31
- Stochastic Oscillator
- BIOX 30.77
- DRUG 50.83
About BIOX Bioceres Crop Solutions Corp.
Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.